WO2017032111A1 - Use of dihydroxyacetone in preparation of anti-tumour drug - Google Patents

Abstract

Provided is a use of dihydroxyacetone in the preparation of a drug, the drug being used for treating a tumour.

Description

Use of dihydroxyacetone in the preparation of antitumor drugs

Priority information

The application number is 201510523222.6, the application date is August 24, 2015, the application number is 201510867132.9, the application date is December 1, 2015, and the application number is 201510867079.2. The application date is December 1, 2015, and the application date is The priority of the Chinese Patent Application of the State Intellectual Property Office is hereby incorporated by reference in its entirety for all its purposes as being expressly incorporated herein by reference.

Technical field

The invention belongs to the field of medicines, and in particular relates to a novel use of a compound, in particular to its use in the preparation of a medicament for antitumor.

Background technique

1,3-Dihydroxyacetone, English name 1,3-dihydroxyaeetone or dihydroxyacetone, abbreviated as DHA, is the simplest three-keto syrup, the appearance is white or off-white powdery crystal, has a sweet, cool taste, easy to absorb moisture And decomposed. In general, it is a crystal of dimer (1,4-Dioxane), which can be slowly dissolved in 1 part of water or 15 parts of ethanol, slightly soluble in ether, but becomes monomer after dissolution or heating, and its monomer Soluble in water, ethanol, acetone and ether and other organic solvents, melting point of 75 ~ 80 ° C, water solubility > 250g · L ^-1 (20 ° C), stable at pH 6.0, is an important chemical, biochemical raw materials , pharmaceutical, pesticide synthesis intermediates and multifunctional food additives, the use is very extensive.

Dihydroxyacetone has the functions of moisturizing, sunscreen and anti-ultraviolet radiation, can prevent excessive evaporation of skin moisture, and can be used as a raw material for cosmetics, especially as a sunscreen. Dihydroxyacetone is an intermediate product of sugar metabolism and plays an important role in the process of glucose metabolism. It has the effect of reducing body fat and increasing lean meat rate. Supplementation with dihydroxyacetone can increase the body's metabolic rate and fatty acid oxidation, potentially can effectively burn fat and reduce body fat, thus reducing weight, reducing the incidence of related diseases, and improving insulin sensitivity and reducing high cholesterol diet. The level of plasma cholesterol, long-term supplementation can increase blood sugar utilization and save muscle glycogen, and athletes can improve aerobic endurance.

Although the use of dihydroxyacetone (DHA) is extensive, there is currently no report on the effect of its use alone or in combination on antitumor effects.

Cisplatin, chemically known as cis-diaminodichloroplatinum, is a cell cycle non-specific drug that is cytotoxic and inhibits the DNA replication process of cancer cells and damages the structure of its cell membrane. It has a strong broad-spectrum anti-cancer effect. effect. However, its side effects are large, and the clinical manifestations are bone marrow transplantation, leukopenia, strong gastrointestinal reactions, nausea, vomiting, diarrhea, etc., irreversible Renal toxicity and kidney failure, neurotoxicity, allergic reactions, electrolyte imbalances, etc. Although cisplatin is so toxic, it is still the first line of clinical treatment of solid tumors due to its exact broad-spectrum anti-tumor effect.

However, it is impossible to enhance the curative effect by increasing the amount of cisplatin in the clinic. Therefore, the establishment of a combination regimen of cisplatin can significantly enhance the antitumor effect without increasing its toxicity, and has been an important topic in oncology research.

Summary of the invention

The present invention aims to solve at least one of the technical problems in the related art to some extent.

This invention relates to new uses of dihydroxyacetone.

The novel use of the present invention mainly includes the use of dihydroxyacetone in the preparation of antitumor drugs. The novel use of dihydroxyacetone provided by the present invention exhibits relatively good activity against various cancers. In addition, dihydroxyacetone has been widely used in human body and is a chemical substance with good safety. Therefore, the new use provided by the present invention has newly expanded the application of the substance in human body, and is expected to be in health food, medicine, etc. The field gets more applications.

The antitumor type of dihydroxyacetone provided by the present invention is not particularly limited, and examples thereof include malignant melanoma, malignant lymphoma, digestive organ cancer, lung cancer, esophageal cancer, gastric cancer, colon cancer, rectal cancer, colon cancer, and ureteral tumor. Gallbladder cancer, biliary tract cancer, breast cancer, liver cancer, pancreatic cancer, testicular tumor, upper jaw cancer, tongue cancer, lip cancer, oral cancer, laryngeal cancer, laryngeal cancer, ovarian cancer, uterine cancer, prostate cancer, thyroid cancer, brain tumor, sarcoma , hemangioma, leukemia, polycythemia vera, neuroblastoma, retinoblastoma, myeloma, bladder tumor, osteosarcoma, muscle tumor, skin cancer, basal cell carcinoma, cutaneous cancer, skin metastasis, skin Melanoma and the like.

According to a particular embodiment of the invention, the tumor may be a nervous system tumor including, but not limited to, neuroblastoma, glioma.

According to a particular embodiment of the invention, the tumor may be a digestive system tumor including, but not limited to, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer.

According to a particular embodiment of the invention, the tumor may be a reproductive, urinary system tumor including, but not limited to, cervical cancer, breast cancer, ovarian cancer, prostate cancer, bladder cancer.

According to a specific embodiment of the present invention, the tumor may be a skin and bone, joint system tumor, including but not limited to melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma.

According to a particular embodiment of the invention, the tumor may be a respiratory tumor, including but not limited to lung cancer, throat cancer, oral cancer.

According to a particular embodiment of the invention, the tumor can be a blood and gland tumor, including but not limited to leukemia, lymphoma, thyroid cancer.

According to an aspect of the invention, the invention provides the use of dihydroxyacetone for the preparation of a medicament for the treatment of a tumor.

According to some embodiments of the invention, the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood, and a gland tumor. At least one.

According to a specific embodiment of the present invention, the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer, bladder cancer. At least one of melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

According to another aspect of the invention, the invention provides the use of dihydroxyacetone in the treatment of a tumor.

According to some embodiments of the invention, the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood, and a gland tumor. At least one.

According to a specific embodiment of the present invention, the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer, bladder cancer. At least one of melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

According to still another aspect of the present invention, the present invention provides a method of treating a tumor comprising administering to a patient dihydroxyacetone.

According to some embodiments of the invention, the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood, and a gland tumor. At least one.

According to a specific embodiment of the present invention, the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer, bladder cancer. At least one of melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

According to still another aspect of the present invention, the present invention provides an antitumor pharmaceutical composition comprising dihydroxyacetone as an active ingredient.

According to some embodiments of the invention, the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood, and a gland tumor. At least one.

According to a specific embodiment of the invention, the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer and bladder cancer. At least one of melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

The invention provides an anti-tumor application of a combination of dihydroxyacetone and cisplatin.

According to still another aspect of the present invention, the present invention provides an antitumor pharmaceutical composition comprising dihydroxyacetone and cisplatin as active ingredients. Dihydroxyacetone and cisplatin have a certain synergistic effect in the treatment of tumors. The combination of dihydroxyacetone and cisplatin is superior to the treatment of tumors with dihydroxyacetone or cisplatin alone, and dihydroxyacetone does not increase the side effects of cisplatin.

According to some embodiments of the invention, the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood, and a gland tumor. At least one.

According to a specific embodiment of the invention, the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer and bladder cancer. At least one of melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

According to still another aspect of the present invention, the present invention provides an antitumor drug combination consisting of dihydroxyacetone and cisplatin. Dihydroxyacetone and cisplatin have a certain synergistic effect in the treatment of tumors. The combination of dihydroxyacetone and cisplatin is superior to the treatment of tumors with dihydroxyacetone or cisplatin alone, and dihydroxyacetone does not increase the side effects of cisplatin.

According to a particular embodiment of the invention, the dihydroxyacetone in the pharmaceutical combination may be in the form of an oral preparation, and the cisplatin may be in the form of an injection.

According to some embodiments of the invention, the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood, and a gland tumor. At least one.

According to a specific embodiment of the invention, the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer and bladder cancer. At least one of melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

According to still another aspect of the present invention, the present invention provides the use of dihydroxyacetone for the preparation of a medicament for use in anti-tumor, simultaneous administration of dihydroxyacetone and cisplatin to a subject. The mode of administration can be according to their respective conventional routes of administration. Diameter, usage and frequency.

According to some embodiments of the invention, the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood, and a gland tumor. At least one.

According to a specific embodiment of the invention, the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer and bladder cancer. At least one of melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

According to still another aspect of the present invention, the present invention provides the use of dihydroxyacetone in the treatment of a tumor, wherein the subject is simultaneously administered with dihydroxyacetone and cisplatin. The mode of administration can be in accordance with their respective usual routes of administration, dosage and frequency.

According to some embodiments of the invention, the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood, and a gland tumor. At least one.

According to a specific embodiment of the invention, the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer and bladder cancer. At least one of melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

According to still another aspect of the present invention, the present invention provides a method of treating a tumor comprising administering to a patient dihydroxyacetone, wherein the subject is simultaneously administered with dihydroxyacetone and cisplatin. The mode of administration can be in accordance with their respective usual routes of administration, dosage and frequency.

According to some embodiments of the invention, the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood, and a gland tumor. At least one.

According to a specific embodiment of the invention, the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer and bladder cancer. At least one of melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

According to still another aspect of the present invention, the present invention provides the use of a combination of dihydroxyacetone and cisplatin for the preparation of a medicament for use in anti-tumor. Dihydroxyacetone and cisplatin have a certain synergistic effect in the treatment of tumors. The combination of dihydroxyacetone and cisplatin is superior to the treatment of tumors with dihydroxyacetone or cisplatin alone, and dihydroxyacetone does not increase the side effects of cisplatin.

According to some embodiments of the invention, the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood, and a gland tumor. At least one.

According to a specific embodiment of the invention, the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer and bladder cancer. At least one of melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

According to yet another aspect of the invention, the invention provides the use of a combination of dihydroxyacetone and cisplatin in the treatment of a tumor. Dihydroxyacetone and cisplatin have a certain synergistic effect in the treatment of tumors. The combination of dihydroxyacetone and cisplatin is superior to the treatment of tumors with dihydroxyacetone or cisplatin alone, and dihydroxyacetone does not increase the side effects of cisplatin.

According to some embodiments of the invention, the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood, and a gland tumor. At least one.

According to a specific embodiment of the invention, the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer and bladder cancer. At least one of melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

According to still another aspect of the present invention, the present invention provides a method of treating a tumor comprising administering to a patient a combination of dihydroxyacetone and cisplatin. Dihydroxyacetone and cisplatin have a certain synergistic effect in the treatment of tumors. The combination of dihydroxyacetone and cisplatin is superior to the treatment of tumors with dihydroxyacetone or cisplatin alone, and dihydroxyacetone does not increase the side effects of cisplatin.

According to some embodiments of the invention, the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood, and a gland tumor. At least one.

According to a specific embodiment of the invention, the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer and bladder cancer. At least one of melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

According to still another aspect of the present invention, the present invention provides a kit for antitumor comprising dihydroxyacetone and cisplatin. Dihydroxyacetone and cisplatin have a synergistic effect in the treatment of tumors. The combination of dihydroxyacetone and cisplatin is more effective than tumor treatment with dihydroxyacetone or cisplatin alone, and dihydroxyacetone does not increase cisplatin. toxic side effect.

According to a particular embodiment of the invention, the dihydroxyacetone and cisplatin in the kit are placed in separate containers.

According to a particular embodiment of the invention, the dihydroxyacetone is in the form of an oral preparation and the cisplatin is in the form of an injection.

According to a particular embodiment of the invention, the weight ratio of dihydroxyacetone to cisplatin in the kit is (3375-4125):1. Preferably, the weight ratio of dihydroxyacetone to cisplatin is 3750:1.

According to some embodiments of the invention, the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood, and a gland tumor. At least one.

According to a specific embodiment of the invention, the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer and bladder cancer. At least one of melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

According to yet another aspect of the invention, the invention provides the use of a combination of dihydroxyacetone and cisplatin for the preparation of a kit for use in anti-tumor.

According to some embodiments of the invention, the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood, and a gland tumor. At least one.

According to a specific embodiment of the invention, the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer and bladder cancer. At least one of melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

The application provided by the present invention includes both the application in malignant tumors and the application in benign tumors.

According to a particular embodiment of the invention, dihydroxyacetone can be used to inhibit cancer metastasis and is particularly useful as a post-surgical cancer metastasis inhibitor.

It should be noted that the term "dihydroxyacetone" as used herein is to be understood broadly, that is, it may include dihydroxyacetone in a monomeric form, and should also cover the common forms of dihydroxyacetone, such as various crystal forms, Dimer or multimer, hydrate, etc.

According to some embodiments of the invention, the dihydroxyacetone may be a monomer, a dimer or a multimer.

For the application of the present invention, dihydroxyacetone can be administered in human or animal in various forms, and can be oral, intravenous, intramuscular, subcutaneous or intradermal, intrarectal, mucosal, etc. the way. The form of the oral preparation can be exemplified by tablets, pills, granules, powders, capsules, oral liquids, suspensions, emulsions, syrups. Wait. The non-oral preparation may, for example, be a transdermal absorption agent such as an injection, a drop, a nasal drop, an inhalant, a suppository, an ointment, a cream, a powder coating agent or a patch. The use of the present invention also includes the incorporation of dihydroxyacetone into a pellet and a sustained release formulation prepared using known techniques.

The medicament of the present invention is suitably used in the form of a pharmaceutical composition. Such compositions may be combined in a conventional manner with one or more pharmaceutically acceptable carriers or excipients. If possible, dihydroxyacetone is administered as a drug substance therapeutically.

When the pharmaceutical composition of the present invention is prepared into a pharmaceutical preparation, a pharmaceutically acceptable carrier can be added as needed. Dihydroxyacetone is used as one of the main or main drugs.

The pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier as needed, wherein dihydroxyacetone is a pharmaceutically active ingredient, which may be 0.01-99.99% by weight in the preparation, and the balance being a pharmaceutically acceptable carrier. The pharmaceutical preparation of the present invention is in the form of a unit dosage form, which means a unit of the preparation, such as each tablet of the tablet, each capsule of the capsule, each bottle of the oral solution, granules per bag, and each injection. Branch and so on.

The pharmaceutical composition of the present invention, which is orally administered, may contain conventional excipients such as a binder, a filler, a diluent, a tablet, a lubricant, a disintegrant, a coloring agent, a flavoring agent, and a moisturizing agent. The tablets can be coated if necessary.

Suitable fillers include cellulose, mannitol, lactose and other similar fillers. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycolate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulfate.

Solid oral compositions can be prepared by conventional methods such as mixing, filling, tableting, and the like. Repeated mixing allows the active material to be distributed throughout those compositions that use large amounts of filler.

The oral liquid preparation may be in the form of, for example, an aqueous or oily suspension, solution, emulsion, syrup or elixir, or may be a dry product which may be formulated with water or other suitable carrier before use. Such liquid preparations may contain conventional additives such as suspending agents such as sorbitol, syrup, methylcellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel or hydrogenated edible fats. Emulsifiers such as lecithin, sorbitan monooleate or gum arabic; non-aqueous vehicles (which may include edible oils), such as almond oil, fractionated coconut oil, oily esters of esters such as glycerol, propylene glycol or ethanol; The agent, for example, p-hydroxybenzyl or propylparaben or sorbic acid, and if desired, may contain conventional flavoring or coloring agents.

For injection, the liquid unit dosage form prepared contains the active substance of the invention and a sterile vehicle. This compound can be suspended or dissolved depending on the carrier and concentration. The solution is usually prepared by dissolving the active substance in a carrier, sterilizing it by filtration before filling it into a suitable vial or ampoule, and then sealing. Excipients such as a local anesthetic, preservative and buffer may also be dissolved in such a carrier. To increase its stability, the composition can be frozen after filling the vial and the water removed under vacuum.

The pharmaceutical composition of the present invention may optionally be added to a suitable pharmaceutically acceptable carrier when prepared as a medicament, the pharmaceutically acceptable carrier being selected from the group consisting of: mannitol, sorbitol, sodium metabisulfite, sodium hydrogen sulfite, sulfur Sodium sulfate, cysteine hydrochloride, thioglycolic acid, methionine, vitamin C, disodium EDTA, calcium EDTA, monovalent alkali metal carbonate, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulfuric acid , phosphoric acid, amino acid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivatives, cellulose and their derivatives , alginate, gelatin, polyvinylpyrrolidone, glycerin, earth temperature 80, agar, calcium carbonate, calcium hydrogencarbonate, surfactant, polyethylene glycol, cyclodextrin, β-cyclodextrin, phospholipids, Kaolin, talc, calcium stearate, magnesium stearate, and the like.

DRAWINGS

The above and/or additional aspects and advantages of the present invention will become apparent and readily understood from

1 is a graph showing IC50 results of dihydroxyacetone to H460, HT29, and SGC7901 cell lines according to Example 1 of the present invention;

2 is an IC ₅₀ statistical result of dihydroxyacetone to HepG2, HCT116, SH-SY5Y, C-33A, and MDA-MB-231 cell lines according to Example 1 of the present invention.

Figure 3 is a graph showing statistical results of relative tumor volume of each group in Example 13 according to the present invention;

Figure 4 is a graph showing the results of body weight statistics of each group of experimental animals in Example 13 according to the present invention;

Figure 5 is a graph showing statistical results of tumor weight of each group in Example 13 according to the present invention;

Figure 6 is a schematic illustration of a medicine cartridge in accordance with Example 16 of the present invention.

Detailed description of the invention

The embodiments of the present invention are described in detail below, and the examples of the embodiments are illustrated in the drawings, wherein the same or similar reference numerals are used to refer to the same or similar elements or elements having the same or similar functions. The embodiments described below with reference to the accompanying drawings are intended to be illustrative of the invention and are not to be construed as limiting.

Example

Example 1

The pharmaceutical use of dihydroxyacetone in the present invention is demonstrated by the following experiments:

1. Experimental method

1.1 Materials and equipment

1.1.1 Reagents

1.1.2 consumables

1.1.3 equipment

1.1.4 Experimental drugs

Commercially available 1,3-dihydroxyacetone solid powder, 15 g of this powder was added per 100 mL of 5% glucose (infusion bottle), and filled into 100 bottles.

Control compound: cisplatin (DDP): Qilu Pharmaceutical Co., Ltd., batch number: 2WA2A1404016A, 20 mg/bottle; a 1 mg/ml stock solution was prepared using a 5% dextrose solution and stored at -20 °C.

1.2 Experimental methods

1.2.1 Determination of osmotic pressure

The sample was diluted to different concentrations in RPMI-1640 medium, and then used by German LOSER ice point osmotic pressure The instrument measures the osmotic pressure of the sample.

1.2.2 Cell culture conditions

1.2.3 Cell Vaccination

After digesting cells and counting (suspensing cells directly counting), the cells were diluted to 1.25×10 ⁵ /ml, inoculated into 384-well plates (5000 cells/well) at 40 μl per well, then centrifuged at 1500 rpm for 1 min, and placed in an incubator for incubation. overnight.

1.2.4 Cell Administration

发光法细胞活力检测试剂盒检测细胞活力。The drug was diluted to 5× with 5% glucose solution, 10 μl per well, 4 replicate wells per concentration (n=4), and the incubator was further cultured for 72 h.

The luminescence cell viability assay kit detects cell viability.

According to the molecular weight conversion, the concentration of the cells administered is as follows:

Concentration setting mM 1 20 2 15 3 10 4 5 5 2.5 6 1.25

1.2.5 Detection method

Add equal volume of CellTiter-Glo reagent to the medium, shake on a shaker for 5 min, shake at 1500 rpm for 1 min, incubate at room temperature for 15 min in the dark, and detect chemiluminescence at BMG PHERAstar.

The cell viability calculation formula is as follows:

Viability% = 100% × (LUM _{sample to be tested -} LUM _blank ) / (LUM _{solvent control -} LUM _blank )

1.2.6 Sample IC ₅₀ calculation

Fitting using Prism 6 Log [concentration] - cell viability curve, the samples for each cell line IC _50.

2 experimental results

The effect of dihydroxyacetone on tumor cell proliferation is shown in Figures 1, 2 and Table 1.

Note: *, indicating that the sample IC50 is calculated as the concentration of dihydroxyacetone;

N/A means that IC ₅₀ is not obtained.

It can be seen from the results that dihydroxyacetone has a broad spectrum of anti-tumor cell proliferation effects, and the IC ₅₀ (semi-inhibitory concentration) values can be obtained for the 34 common tumor cell lines involved in the experiment. It shows that dihydroxyacetone has different inhibitory effects on common tumors, especially for sarcoma, neuroblastoma, myeloma, colon cancer, lung cancer, stomach cancer, leukemia and thyroid tumor.

In summary, the novel use of the dihydroxyacetone provided by the present invention exhibits relatively good activity against various cancers. In addition, dihydroxyacetone has been widely used in human body and is a chemical substance with good safety. Therefore, the new use provided by the present invention has newly expanded the application of the substance in human body, and is expected to be in health food, medicine, etc. The field gets more applications.

Example 2

Preparation of tablets

As a pharmaceutically active ingredient, dihydroxyacetone is added to a pharmaceutical carrier and prepared according to conventional techniques of preparation, such as the following preparation method:

10 mg of dihydroxyacetone, 200 mg of starch, 100 mg of powdered sugar, and an appropriate amount of magnesium stearate were mixed with a starch paste as a binder, granulated, air-dried, sized, and tableted to obtain tablets.

Example 3

Preparation of hard capsules

As a pharmaceutically active ingredient, dihydroxyacetone is added to a pharmaceutical carrier and prepared according to conventional techniques of preparation, such as the following preparation method:

10 mg of dihydroxyacetone, 200 mg of starch, 100 mg of powdered sugar, and an appropriate amount of magnesium stearate, using starch paste as a binder, mixing, granulating, air drying, whole granules, and capsules.

Example 4

Preparation of soft capsules

As a pharmaceutically active ingredient, dihydroxyacetone is added to a pharmaceutical carrier and prepared according to conventional techniques of preparation, such as the following preparation method:

10 mg of dihydroxyacetone, soybean oil 100 mg, and polyethylene glycol 100 mg were prepared into soft capsules using gelatin as a capsule.

Example 5

Preparation of oral liquid

As a pharmaceutically active ingredient, dihydroxyacetone is added to a pharmaceutical carrier and prepared according to conventional techniques of preparation, such as the following preparation method:

10 mg of dihydroxyacetone, 50 mg of glycerin, 100 mg of sucrose, an appropriate amount of essence, and water was added to 10 ml.

Example 6

Preparation of granules

As a pharmaceutically active ingredient, dihydroxyacetone is added to a pharmaceutical carrier and prepared according to conventional techniques of preparation, such as the following preparation method:

10 mg of dihydroxyacetone, 200 mg of dextrin, 100 mg of powdered sugar, water as a binder, mixing, granulating, air drying, whole granules, and packaging.

Example 7

Preparation of pills

As a pharmaceutically active ingredient, dihydroxyacetone is added to a pharmaceutical carrier and prepared according to conventional techniques of preparation, such as the following preparation method:

10 mg of dihydroxyacetone, 200 mg of sodium carboxymethylcellulose was added, and the mixture was uniformly mixed, and the pellet was prepared and dried to prepare 1000 pellets, which were obtained by coating a film.

Example 8

Preparation of dry suspension

As a pharmaceutically active ingredient, dihydroxyacetone is added to a pharmaceutical carrier and prepared according to conventional techniques of preparation, such as the following preparation method:

10 g of dihydroxyacetone, 100 g of hydroxypropylmethylcellulose, 200 g of microcrystalline cellulose, 200 g of sucrose, mixed: soft material made of 50% ethanol, granulated, air-dried, granulated, packaged.

Example 9

Preparation of suppository

As a pharmaceutically active ingredient, dihydroxyacetone is added to a pharmaceutical carrier and prepared according to conventional techniques of preparation, such as the following preparation method:

10g dihydroxyacetone, cocoa butter 600g, molten matrix, added drugs, mixed, injection molded, cooled, scraped, taken out, that is.

Example 10

Preparation of pills

As a pharmaceutically active ingredient, dihydroxyacetone is added to a pharmaceutical carrier and prepared according to conventional techniques of preparation, such as the following preparation method:

5g dihydroxyacetone, 60g polyethylene glycol 6000,

Take dihydroxyacetone, add it to the already melted polyethylene glycol 6000, the temperature is 60-90 ° C, melt and stir evenly, then transfer it into the drip irrigation of the dropping machine (insulation 70-90 ° C), drop 5- In the liquid paraffin or methyl silicone oil at 17 ° C, the dropping pills are taken out, the liquid paraffin or methyl silicone oil is removed, the pellet is washed, and dried to obtain 1000 pills of dropping pills.

Example 11

Preparation of dispersible tablets

As a pharmaceutically active ingredient, dihydroxyacetone is added to a pharmaceutical carrier and prepared according to conventional techniques of preparation, such as the following preparation method:

5g dihydroxyacetone, lactose 18g, pregelatinized starch 25g, microcrystalline cellulose 35g, low substituted hydroxypropyl cellulose 7g, polyvinylpyrrolidone 6g, micronized silica gel 1g. Water as binder, mixing, granulation, air drying , whole grain, tableting.

Example 12

Preparation of sugar-free granules

As a pharmaceutically active ingredient, dihydroxyacetone is added to a pharmaceutical carrier and prepared according to conventional techniques of preparation, such as the following preparation method:

10 mg of dihydroxyacetone, stevioside 4 mg dextrin 440 mg. Take component 1, dextrin, stevia mixed, add 95% ethanol to make soft material, 14 mesh sieve granulation, 50 ~ 55 ° C drying, 12 mesh whole grain, sub-package, that is.

Example 13

1 test material

1.1 Test sample

Name: Dihydroxyacetone (DHA) solid powder

Provided by: Suzhou Yabao Drug Development Co., Ltd.

Positive control: Cisplatin for injection, batch number: 2WA2A1408055A, manufacturer: Qilu Pharmaceutical Co., Ltd., specification: 20mg/bottle

1.2 test animals

Species, strains and ranks: Balb/c-nude nude mice, SPF grade

Source: Shanghai Lingchang Biotechnology Co., Ltd.

License number: SCXK (Shanghai) 2013-00185

Animal certificate number: 2013001812253

Weight: 16-18g (on arrival)

Gender: Male

2 test plan

Nude mice were subcutaneously inoculated with H460 cells (human large cell lung cancer cell line). When the tumor grew to a volume of about 100 mm ³ , 36 nude mice with similar tumor volume and good shape were selected from 70 nude mice, and divided into 6 groups. Group of 6 animals;

DHA group: p.o., administration volume is 0.1mL/10g, bid, for three weeks;

DHA+Cisplatin group: dihydroxyacetone (DHA): po, administration volume 0.1 mL/10 g, bid; Cisplatin: 4 mg/kg, injection volume 0.1 mL/10 g, ip, once every 5 days for 3 weeks ;

Cisplatin group: 4 mg/kg, injection volume 0.1 mL/10 g, i.p, once every 5 days for a total of three weeks;

Blank group: 0.9% sodium chloride injection, the same as the DHA group.

3 experimental methods

3.1 inoculation

3.1.1 Resuscitation and expansion of H460 cells;

3.1.2 To a sufficient number of cells to be expanded, collect the cells, and prepare a cell suspension with a concentration of 2×10 ⁷ cells/mL using serum-free 1640 medium;

3.1.3 nude mice were injected subcutaneously on the right side of the back, 0.1 mL/only, that is, the number of cells per nude mouse was 2×10 ⁶ ;

3.1.4 A total of 70 nude mice were inoculated, and the tumor condition and tumor size were observed after inoculation.

3.2 group administration

3.2.1 When the tumor grew to a volume of about 100 mm ³ , 36 nude mice with similar tumor volume and good shape were selected from 70 nude mice, and divided into 6 groups, 6 in each group.

3.2.2 grouping

Same as "2 test plan"

3.3 drug preparation

DHA: Weigh 15.0 g of solid powder in a 100 mL volumetric flask, dilute to the mark with 5% glucose injection, and shake until ultrasonically dissolved completely. Refrigerated at 4 ° C when not in use.

DHA+Cisplatin: Weigh 15.0 g of solid powder dihydroxyacetone in a 100 mL volumetric flask, dilute to the mark with 5% glucose injection, and shake until ultrasonically dissolved completely. A solution of 0.6 mg/mL cisplatin solution 4.0 mL and 2.0 mL of physiological saline was added to prepare a 0.4 mg/mL (4 mg/kg) cisplatin solution, which was chilled at 4 ° C when not used.

All samples were configured every three days.

3.4 Measurement

Tumor volume and body weight were measured 3 times per week from the first day of administration. On the 22nd day, the nude mice were sacrificed, the tumors were removed and photographed, and the tumor inhibition rate was calculated.

3.5 Evaluation indicators

Tumor volume change; animal weight change; final tumor weight.

4 detection indicators and calculation methods

4.1 tumor volume (TV)

The calculation formula is: TV = 1/2 × a × b ² , where a and b represent length and width, respectively.

4.2 Relative tumor volume (RTV)

The formula is: RTV = TV _t /TV ₁ , where TV ₁ is the tumor volume when the cage is administered (ie, d ₁ ), and TV _t is the tumor volume at each measurement.

4.3 Relative tumor proliferation rate T/C (%)

The calculation formula is:

T _RTV : treatment group RTV; C _RTV : blank control group RTV.

4.4 tumor weight inhibition rate IR (%)

The calculation formula is:

T _TW : tumor weight of treatment group; C _TW : tumor weight of blank control group; TW (tumor weight): tumor weight.

5 test results

The specific results are shown in Table 2, Table 3 and Figure 3, Figure 4 and Figure 5.

Table 2: Number of animals, body weight, tumor volume (TV), relative tumor volume (RTV), relative tumor growth rate (T/C)

***P<0.01v.s.Blank(RTV)*:0.01<P<0.05v.s.Blank(RTV)

Table 3: Tumor weight and tumor weight inhibition rate

*:0.01<P<0.05v.s.Blank

6 results discussion

6.1 Tumor growth: The results showed that the tumor volume of each group had a good dispersion, and the standard deviation was less than 1/4 of the mean. The tumor in the blank group grew well, and RTV=(1797.4±657.6) at the end of the experiment.

6.2 Body weight: During the whole experiment, the Cisplatin group and DHA+Cisplatin showed significant weight loss, and the other groups grew normally.

6.3Cisplatin group: the toxicity was very obvious, the body weight decreased significantly, the body temperature decreased, the body weight decreased by about 16.7% at the end of the test, and the animal state was poor. The dosing schedule was once every 5 days, and the final dose was 4 times. . Cisplatin had a significant anti-tumor effect (P=0.04), and finally its T/C=60.3%, and the tumor weight inhibition rate was 44.6%. This also indicates that the test system is reliable and can be used for drug efficacy evaluation.

6.4 DHA group: no toxic reaction, no obvious anti-tumor effect in this test model.

6.5 DHA+Cisplatin group: toxic reaction, showing weight loss, decreased body temperature, weight loss at the end of the test was about 15.7%, and the value was reduced compared with Cisplatin alone. DHA is administered twice a day, Cisplatin is scheduled to be administered every 5 days, and the final dose is 4 times. The anti-tumor effect of this group was very obvious (P=0.0059), and finally its T/C=44.9%, and the tumor weight inhibition rate was 53.3%.

6.6 Summary

In this trial, the DHA+Cisplatin group was significantly more potent in the human large cell lung cancer H460 cell xenograft model than the Cisplatin group, and did not increase the toxicity of the chemical cisplatin. It is believed that DHA can be combined with the chemical cisplatin. Play a better anti-tumor effect.

Example 14

Commercially available dihydroxyacetone (DHA) with a white powdery crystal of sweetness. 300 g of DHA, 200 g of hypromellose was added, and 40 tablets of tablets were prepared by a conventional method, and sealed. 0.0792 g of cisplatin and 0.7 g of sodium chloride were added to 80 ml of distilled water, and aseptically packaged as 4 injections. DHA tablets and cisplatin injections are placed in the same package and packaged as a kit in a conventional manner.

Example 15

Commercially available dihydroxyacetone (DHA) 312 g, divided into an average of 40 parts, was sealed and packaged into sachets under dry room temperature. Cisplatin 0.076g, divided into 4 parts on average, sealed package as a vial. When used, it is dissolved by glucose for injection. DHA orally, 0.13g / kg (calculated according to human body weight of 60kg, the same below), twice a day, continuous use for 20 days. Intravenous infusion or intramuscular injection of cisplatin, 0.317mg/kg, once every 5 days.

Example 16

The anti-tumor kit is shown in Figure 6.

The vial (101) contains 4 vials (102), which are respectively sealed with 5 ml of cisplatin injection (concentration 3.98 mg/ml). Another 40 sealed packaging bags (103) were provided with 6.75 g of dihydroxyacetone particles. A sterile syringe (104) and a medication cup (105) are also provided in the kit. When in use, the dihydroxyacetone particles are placed in the medication cup (105), dissolved in an appropriate amount of water, orally administered after meals, 112.5 mg/kg twice a day. Cisplatin was intramuscularly injected with a syringe (104) at 0.339 mg/kg once every 5 days.

It should be noted that the terms "first" and "second" are used for descriptive purposes only, and are not to be construed as indicating or implying a relative importance or implicitly indicating the number of technical features indicated. Thus, features defining "first" and "second" may include one or more of the features either explicitly or implicitly. Further, in the description of the present invention, the meaning of "a plurality" is two or more unless otherwise specified.

In the description of the present specification, the description with reference to the terms "one embodiment", "some embodiments", "illustrative embodiment", "example", "specific example", or "some examples", etc. Particular features, structures, materials or features described in the examples or examples are included in at least one embodiment or example of the invention. In the present specification, the schematic representation of the above terms does not necessarily mean the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in a suitable manner in any one or more embodiments or examples.

Although specific embodiments of the invention have been described in detail, those skilled in the art will understand. Various modifications and alterations of the details are possible in light of the teachings of the invention. The full scope of the invention is given by the appended claims and any equivalents thereof.

Claims (46)

The use of dihydroxyacetone in the preparation of a medicament for the treatment of a tumor. The use according to claim 1, wherein the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood. And at least one of glandular tumors. The use according to claim 1, wherein the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, At least one of prostate cancer, bladder cancer, melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer. The use of dihydroxyacetone in the treatment of tumors. The use according to claim 4, wherein the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood And at least one of glandular tumors. The use according to claim 4, wherein the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, At least one of prostate cancer, bladder cancer, melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer. A method of treating a tumor comprising administering to a patient dihydroxyacetone. The method according to claim 7, wherein the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood. And at least one of glandular tumors. The method according to claim 7, wherein the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, At least one of prostate cancer, bladder cancer, melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer. An antitumor pharmaceutical composition comprising dihydroxyacetone as an active ingredient. The pharmaceutical composition according to claim 10, wherein the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, and a respiratory tumor. At least one of blood and gland tumors. The pharmaceutical composition according to claim 10, wherein said tumor comprises a neuroblast selected from the group consisting of Cancer, glioma, colon cancer, rectal cancer, liver cancer, stomach cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, prostate cancer and bladder cancer, melanoma, epidermal squamous cell carcinoma, rhabdomyomas, multiple myeloma At least one of sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer. An antitumor pharmaceutical composition comprising dihydroxyacetone and cisplatin as active ingredients. The pharmaceutical composition according to claim 13, wherein the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, and a respiratory tumor. At least one of blood and gland tumors. The pharmaceutical composition according to claim 13, wherein the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, and ovary At least one of cancer, prostate cancer, bladder cancer, melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer. An antitumor drug combination characterized by consisting of dihydroxyacetone and cisplatin. The pharmaceutical combination according to claim 16, wherein the dihydroxyacetone is in the form of an oral preparation, and the cisplatin is in the form of an injection. The pharmaceutical combination according to claim 16, wherein the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, At least one of blood and gland tumors. The pharmaceutical combination according to claim 16, wherein the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer. At least one of prostate cancer, bladder cancer, melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer. The use of dihydroxyacetone in the preparation of a medicament for the treatment of a tumor, wherein the subject is simultaneously administered with dihydroxyacetone and cisplatin. The use according to claim 20, wherein the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood And at least one of glandular tumors. The use according to claim 20, wherein the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, At least one of prostate cancer, bladder cancer, melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer. The use of dihydroxyacetone in the treatment of tumors wherein dihydroxyacetone and cisplatin are administered simultaneously to the subject. The use according to claim 23, wherein the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood And at least one of glandular tumors. The use according to claim 23, wherein the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, At least one of prostate cancer, bladder cancer, melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer. A method for treating a tumor, comprising administering a dihydroxyacetone to a patient, wherein the subject simultaneously administered dihydroxyacetone and cisplatin. The method according to claim 26, wherein said tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood And at least one of glandular tumors. The method according to claim 26, wherein said tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, At least one of prostate cancer, bladder cancer, melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer. The use of a combination of dihydroxyacetone and cisplatin for the preparation of a medicament for the treatment of a tumor. The use according to claim 29, wherein the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood And at least one of glandular tumors. The use according to claim 29, wherein the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, At least one of prostate cancer, bladder cancer, melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer. The use of a combination of dihydroxyacetone and cisplatin in the treatment of tumors. The use according to claim 32, wherein the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood And at least one of glandular tumors. The use according to claim 32, wherein the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, Prostate cancer, bladder cancer, melanoma, epidermal squamous cell carcinoma, rhabdomyomas, multiple myeloma, sarcoma, lung cancer, throat cancer, mouth At least one of luminal cancer, leukemia, lymphoma, thyroid cancer. A method of treating a tumor comprising administering a combination of dihydroxyacetone and cisplatin to a patient. The method according to claim 35, wherein said tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood. And at least one of glandular tumors. The method according to claim 35, wherein said tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, At least one of prostate cancer, bladder cancer, melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer. A kit for anti-tumor, which includes dihydroxyacetone and cisplatin. A kit according to claim 38, wherein dihydroxyacetone and cisplatin are disposed in different containers. The kit according to claim 38, wherein the dihydroxyacetone is in the form of an oral preparation, and the cisplatin is in the form of an injection. The kit according to claim 38, wherein the weight ratio of dihydroxyacetone to cisplatin is (3375-4125):1. The kit according to claim 38, wherein said tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, At least one of blood and gland tumors. The kit according to claim 38, wherein said tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer At least one of prostate cancer, bladder cancer, melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer. The use of a combination of dihydroxyacetone and cisplatin in the manufacture of a kit for the treatment of a tumor. The use according to claim 44, wherein the tumor comprises a tumor selected from the group consisting of a nervous system tumor, a digestive system tumor, a reproductive system tumor, a urinary system tumor, a skin tumor, a bone tumor, a joint system tumor, a respiratory tumor, a blood And at least one of glandular tumors. The use according to claim 44, wherein the tumor comprises a patient selected from the group consisting of neuroblastoma, glioma, colon cancer, rectal cancer, liver cancer, gastric cancer, pancreatic cancer, cervical cancer, breast cancer, ovarian cancer, At least one of prostate cancer, bladder cancer, melanoma, epidermal squamous cell carcinoma, rhabdomyosarcoma, multiple myeloma, sarcoma, lung cancer, throat cancer, oral cancer, leukemia, lymphoma, thyroid cancer.

Images